The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, ProQR Therapeutics N.V (NASDAQ: PRQR) closed at $2.0 down -1.96% from its previous closing price of $2.04. In other words, the price has decreased by -$1.96 from its previous closing price. On the day, 0.86 million shares were traded. PRQR stock price reached its highest trading level at $2.0926 during the session, while it also had its lowest trading level at $1.91.
Ratios:
For a deeper understanding of ProQR Therapeutics N.V’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.36. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.18.
On April 29, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $5.
Citigroup Upgraded its Neutral to Buy on March 10, 2025, while the target price for the stock was maintained at $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRQR now has a Market Capitalization of 210690384 and an Enterprise Value of 120298384. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.34 while its Price-to-Book (P/B) ratio in mrq is 3.14. Its current Enterprise Value per Revenue stands at 7.484 whereas that against EBITDA is -2.759.
Stock Price History:
The Beta on a monthly basis for PRQR is 0.17, which has changed by -0.25547445 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, PRQR has reached a high of $3.10, while it has fallen to a 52-week low of $1.07. The 50-Day Moving Average of the stock is -13.61%, while the 200-Day Moving Average is calculated to be -1.33%.
Shares Statistics:
For the past three months, PRQR has traded an average of 543.28K shares per day and 522320 over the past ten days. A total of 105.35M shares are outstanding, with a floating share count of 70.02M. Insiders hold about 33.45% of the company’s shares, while institutions hold 35.10% stake in the company. Shares short for PRQR as of 1765756800 were 1273703 with a Short Ratio of 2.34, compared to 1763078400 on 778119. Therefore, it implies a Short% of Shares Outstanding of 1273703 and a Short% of Float of 1.7000000000000002.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of ProQR Therapeutics N.V (PRQR) in the stock market.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.1 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.44 and -$0.52 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.62, with 8.0 analysts recommending between -$0.43 and -$0.82.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $6.09M this quarter.It ranges from a high estimate of $11.99M to a low estimate of $2.78M. As of. The current estimate, ProQR Therapeutics N.V’s year-ago sales were $4.85MFor the next quarter, 5 analysts are estimating revenue of $5.53M. There is a high estimate of $8.58M for the next quarter, whereas the lowest estimate is $2.78M.
A total of 5 analysts have provided revenue estimates for PRQR’s current fiscal year. The highest revenue estimate was $25.46M, while the lowest revenue estimate was $15.98M, resulting in an average revenue estimate of $19.53M. In the same quarter a year ago, actual revenue was $21.34MBased on 5 analysts’ estimates, the company’s revenue will be $20.05M in the next fiscal year. The high estimate is $25.32M and the low estimate is $11M.
